NOW Diagnostics has officially acquired the rapid reader product line and related assets of mobile diagnostics company CELLMIC LLC. As technology and healthcare continue to intertwine and evolve, no one sums up the benefits and impact of this acquisition better than our CEO:
“This acquisition will allow us to integrate CELLMIC’s advanced reader technology with our ADEXUSDx® testing platform, which we expect will result in even more accurate results and provide convenience, simplicity and cost benefits to U.S. and international point-of-care testing and consumer healthcare markets. Our ADEXUSDx® product line is built on the ‘lab at your fingertip’ concept as an alternative to laboratory-based testing, and the addition of this new reader technology from CELLMIC is expected to put digital analysis ‘in the palm of your hand.’” -NOW Diagnostics’ CEO, Kevin Clark
Mobile Healthcare and Rapid Diagnostics
In 2012, Holomic launched their first smartphone-based rapid diagnostic test (RDT) reader and soon after established contracts and grants with the US Army, Army Research Office and the National Institutes of Health. In 2015, Holomic/CELLMIC LLC. was named a Technology Pioneer by the World Economic Forum. CELLMIC’s products are CE Mark, and are in use around the world. NOW Diagnostics has been a partner of CELLMIC for over two years.
“We believe that this transaction will enable this superior reader technology to reach its full commercial potential, both in combination with NOW Diagnostics’ rapid tests as well as through continued OEM partnerships.” -CELLMIC’s CEO Neven Karlovac
About NOW Diagnostics, Inc.
NOW Diagnostics, Inc., based in Springdale, Arkansas, is a leader in innovative diagnostics testing. Its ADEXUSDx® product line features a lab at your fingertip, using a single drop of blood to test for a variety of common conditions, illnesses and diseases, with results in a matter of minutes. By eliminating the need to send tests to off-site laboratories, NOW Diagnostics products have the potential to decrease the waiting period to determine test results by days. For more information about NOW Diagnostics, visit www.nowdx.com. For more information about the ADEXUSDx® hCG pregnancy test, including its intended use, features, benefits and limitations, and directions for use, visit www.nowdx.com/products/hcg. For more information on the FIRST TO KNOW® pregnancy test, including its intended use, features, benefits and limitations, and directions for use, visit www.firsttoknow.eu.
About CELLMIC, LLC
Cellmic, LLC is a technology company dedicated to improving patient healthcare with the use of smartphones and biophotonics. We are a licensee of UCLA and collaborate closely with Professor Aydogan Ozcan and his research group at the university. Our first commercialization success was a product line of readers for lateral flow immunoassays that is now part of NOW Diagnostics, Inc. Cellmic continues with the commercialization of other technologies in our portfolio, including microplate readers, lens-free holographic microscopes, and handheld analyzers for blood count, allergens, and mercury contamination. The company earned the Technology Pioneer 2015 award by the World Economic Forum in Davos; was a finalist for the Katerva, Nokia Sensing X-Challenge, and SPIE PRISM awards; and has won numerous government and corporate contracts. For more information see www.cellmic.com.
Press Release published on Business Wire.
NOW Diagnostics Company Contact
Beth Cobb, COO
NOW Diagnostics Media Contact
Dan Snyders, Armada Medical Marketing
CELLMIC, LLC Contact
Neven Karlovac, CEO